



December 6, 2024

Piraeus Medical
Kristin M. Mortenson
VP Quality and Regulatory
7351 Kirkwood Lane North
Suite 116
Maple Grove, Minnesota 55369

Re: K240971

Trade/Device Name: 87 NeuGlide Catheter
Regulation Number: 21 CFR 870.1250
Regulation Name: Percutaneous Catheter
Regulatory Class: Class II
Product Code: QJP, DQY
Dated: November 4, 2024
Received: November 6, 2024

Dear Ms. Mortenson:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"

(<https://www.fda.gov/media/99812/download>) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (<https://www.fda.gov/media/99785/download>).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at <https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system>.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Sara S. Thompson -S

for Naira Muradyan, Ph.D.
Assistant Director
DHT5A: Division of Neurosurgical,
Neurointerventional, and
Neurodiagnostic Devices
OHT5: Office of Neurological and
Physical Medicine Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known)

K240971

Device Name

87 NeuGlide Catheter

Indications for Use (Describe)

The 87 NeuGlide Catheter is indicated for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature.

Type of Use (Select one or both, as applicable)

☒ Prescription Use (Part 21 CFR 801 Subpart D)

☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510(k) Summary, K240971

A. Submitter Information

Submitter's Name:	Piraeus Medical
Address:	7351 Kirkwood Lane Maple Grove, MN 55369
Contact Person:	Jared Hutar
Telephone:	507-782-0184
Email:	quality@piraeusmedical.com
Date of Preparation:	November 4 th , 2024

B. Correspondent Information

Contact Name:	Kristin Mortenson
---------------	-------------------

C. Subject Device

Proprietary Names:	87 NeuGlide Catheter
Common/Usual Name:	Guide Catheter
Classification Name:	Catheter, Percutaneous, Neurovasculature
Product Code:	QJP, DQY
Regulation:	21 CFR 870.1250

D. Predicate Device

Proprietary Name:	TracStar Large Distal Platform
Common/Usual Name:	Guide Catheter
Classification Name:	Catheter, Percutaneous
Product Code:	QJP, DQY
Regulation:	21 CFR. 870.1250
Manufacturer:	Imperative Care Inc.
510(k) #'s:	K203764

E. Device Description:

The Piraeus Medical 87 NeuGlide Catheter is a single lumen guide catheter that provide access to peripheral, coronary and neuro vasculature. The catheter is comprised of a hollow cylindrical tube bonded at the proximal end to a standard luer fitting. The wall of the tube is constructed using a combination of metal coils/braids and medical grade polymers. The catheter features a hydrophilic coating to enhance tracking through tortuous vasculature and facilitate the introduction of interventional devices to the peripheral, coronary and neurovasculature. The 87 NeuGlide guide catheter is compatible with 0.035" or smaller guidewires.

The distal soft tip facilitates smooth tracking past vessel branches. A radiopaque marker provides visual confirmation of the distal tip location under fluoroscopy. The 87 NeuGlide Catheter has an inner diameter of 0.087" (6F compatible), and a maximum outer diameter of 0.100". The catheter is offered in working lengths of 110 and 100 cm. The 87 NeuGlide guide catheter is packaged with a loading tool to aid in insertion of the catheter into a short sheath.

Accessory devices required, but not supplied include:

- Guidewires
- Support/diagnostic catheters
- Introducer sheaths
- Rotating Hemostasis valves (RHVs)

F. Indications for Use:

The 87 NeuGlide Catheter is indicated for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature.

G. Principles of Operation:

The 87 NeuGlide Catheter may be used with support catheters to assist in accessing the target vasculature. Use of the 87 NeuGlide Catheter relies on standard percutaneous interventional techniques, including access site preparation, introducing the catheter portion of the device, advancing the catheter under fluoroscopy, withdrawing the catheter, and closing the access site.

Predicate Comparison:

The predicate device is the Imperative Care TracStar Large Distal Platform cleared under K204764. The predicate and subject devices share the same intended use, basic technology characteristics, and the same performance characteristics, demonstrated through bench and laboratory testing as shown in Table 1.

Table 1: Comparison of Predicate and Subject Device

Device Attribute	Predicate device (K203764)	Subject Device (K240971)
FDA Product Classification	Class II, QJP and DQY, 21 CFR 870.1250	Same
Product Name	TracStar Large Distal Platform	87 NeuGlide Catheter
Indications for Use	The TracStar Large Distal Platform is indicated for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature.	The 87 NeuGlide Catheter is indicated for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature.
Condition Supplied	Sterile and Single Use	Same
Sterilization Method	Ethylene Oxide (EO), SAL 10 ⁻⁶	Same
Inner Diameter (Distal)	0.088"	0.087"
Outer Diameter (Distal)	0.106"	0.100"
Inner Diameter (Proximal)	0.088"	0.087"
Outer Diameter (Proximal)	0.110"	0.100"
Effective Length	80 - 110cm	100 - 110cm
Tip Design	Beveled distal edge, soft, flexible, atraumatic tip	Straight atraumatic tip
Coating	Hydrophilic coating	Same
Materials	Commonly used medical grade plastics & metals with hydrophilic coating.	Same
Packaged Accessories	Rotating Hemostasis Valve (RHV)	Loading Tool
Packaging Configuration	The catheters are placed in a protective polyethylene tube, mounted with accessory RHV onto a polyethylene packaging card, placed into a pouch, sealed and labeled. The sealed pouch and IFU are placed in a labeled shelf carton box.	The catheter is placed in a protective polyethylene tube, mounted with accessory loading tool onto a polyethylene packaging card, placed into a pouch, sealed and labeled. The sealed pouch and IFU are placed in a labeled shelf carton box.

H. Performance Data Supporting Substantial Equivalence:

A summary of the supportive data is presented in [Table 2](#). These tests were performed per company approved protocols, test methods, and performance standards.

Table 2: Tests and Performance Specifications

Test	Test Method Summary [standard and/or guidance]	Results
Visual Inspection	The catheter was examined for surface defects or extraneous matter. The distal tip was inspected to confirm the presence of smooth, tapered or rounded edges	Pass
Dimensional Verification	The catheter outer diameter, inner diameter, usable length, and coating length were measured.	Pass
Delivery, Compatibility, and Retraction (Trackability)	The catheter shall be able to be prepped, inserted, tracked, and retracted and removed per the IFU within a simulated use model without incurring any damage to the catheter. [ISO 10555-1, FDA guidance PTA and Specialty Catheters]	Pass
Flexibility and Kink Resistance	There shall be no kinking of shaft (permanent deformation) after simulated use. [FDA guidance PTA and Specialty Catheters]	Pass
Compatibility with other Devices (external)	The catheter is compatible with introduction through 7F introducer (short) sheath. [ISO 10555-1, FDA guidance PTA and Specialty Catheters]	Pass
Guidewire Compatibility	The catheter shall be able to be delivered over the maximum size guidewire indicated in the product labeling. [ISO 10555-1, FDA guidance PTA and Specialty Catheters]	Pass
Interventional Device Compatibility (internal)	The catheter shall be able to accommodate other interventional devices (e.g., support catheter, diagnostic catheter) up to the maximum size indicated in the product labeling. [ISO 10555-1, FDA guidance PTA and Specialty Catheters]	Pass
Luer Compatibility	Devices and accessories shall be compatible with standard syringe luer fittings per ISO 80369-7 and -20.	Pass
Accessory Compatibility	Devices shall be compatible with accessories such as RHVs and the accessory loading tool.	Pass
Catheter Bond Strength	The catheter shall have sufficient tensile bond strengths in comparison to measured retrieval forces to remain intact throughout a procedure. [ISO 10555-1, FDA guidance PTA and Specialty Catheters]	Pass
Freedom from Leakage – positive pressure	No liquid leakage from the hub or catheter shaft at 317 kPa (46 psi) for 30 seconds. [ISO 10555-1]	Pass
Freedom from Leakage – negative pressure	No air leakage into a 20cc syringe when vacuum pulled for 15 seconds. [ISO 10555-1]	Pass
Kink Resistance	There shall be no kinking of the catheter shaft (permanent deformation) after wrapping around anatomically relevant bend radii. [FDA guidance PTA and Specialty Catheters]	Pass
Pushability	The proximal shaft of the catheter shall have sufficient stiffness that the user can easily push the catheter to the target anatomy without buckling. [ISO 10555-1, FDA guidance PTA and Specialty Catheters]	Pass
Access Force	Catheter shall not require excessive force to safely navigate and track to the target anatomy. [ISO 10555-1, FDA guidance PTA and Specialty Catheters]	Pass
Static Burst	The distal tip of the catheter was blocked, and fluid was	Pass

Test	Test Method Summary [standard and/or guidance]	Results
	injected into the lumen at increasing pressure until the catheter burst per ISO 10555-1 and the static burst pressure was compared with the maximum pressure generated with manual syringe injection.	
Torque Strength	The catheter was navigated through a clinically relevant tortuous path and with the distal tip secured the proximal end was rotated until failure. [FDA guidance PTA and Specialty Catheters]	Pass
Distal Tip Flexibility	Tip flexibility was measured with a force gauge to measure the compressive force exerted by the side of the catheter at a defined distance from the distal tip when the distal tip of the catheter is deflected. Results were compared to the predicate.	Pass
Particulate	The amount of particulate matter generated during simulated use testing was compared to the predicate. [FDA guidance PTA and Specialty Catheters]	Pass
Coating Lubricity, Durability, and Integrity	Durability and lubricity measured the frictional forces with a pinch test. The hydrophilic coating was examined for damage after simulated use.	Pass
Corrosion	Corrosion resistance evaluated the metallic components related to corrosion contacting the intended fluid path. [ISO 10555-1]	Pass
Radiopacity	ASTM F640-23	Pass

I. Biocompatibility Testing

The following biocompatibility testing was conducted for the 87 NeuGlide Catheter:

Test	Test Method Summary	Results
Cytotoxicity - MEM Elution	Tested in accordance with ISO 10993- 5	Pass The test article is considered non-cytotoxic.
Sensitization – Guinea Pig Maximization Sensitization	Tested in accordance with ISO 10993-10	Pass The test article is considered non-sensitizing.
Irritation - Intracutaneous Reactivity	Tested in accordance with ISO 10993- 23	Pass Requirements have been met by the test article.
Systemic Toxicity - Acute Systemic Toxicity Test	Tested in accordance with ISO 10993- 11	Pass Requirements have been met by the test article.
Pyrogenicity - Material Mediated Pyrogenicity Test)	Tested in accordance with ISO 10993- 11 and USP <151>	Pass Requirements have been met by the test article.
Hemocompatibility - Hemolysis (Direct Contact & Extract Method)	Tested in accordance with ASTM F756, and ISO 10993-4	Pass The test article is considered non-hemolytic.
Hemocompatibility - Complement Activation SC5b-9 Assay	Tested in accordance with ISO 10993-4	Pass Requirements have been met by the test article.
Hemocompatibility - In-vivo Thromboresistance	Tested in accordance with ISO 10993- 4	Pass The test article performed similarly to the control article.

J. Sterilization:

The 87 NeuGlide Catheter is sterilized using a validated EO process with a sterility assurance level of 1×10^{-6} validated per the overkill method in accordance with ISO 11135, "Sterilization of Health-Care Products - Ethylene Oxide - Requirements for The Development, Validation and Routine Control of A Sterilization Process For Medical Devices".

K. Shelf Life and Packaging:

Accelerated aging testing based on ASTM F1980 was conducted to verify packaged device performance to support a 6-month shelf-life claim. Device and package performance was verified by functional and performance testing.

L. Conclusions:

As confirmed through the results of bench and lab testing, the subject device and predicate device share the same intended use, basic technological characteristics, and performance characteristics. Based on the results of bench performance testing, the subject and predicate devices are substantially equivalent.